Our mission is to provide hope to those who may have lost faith in finding solutions for complex, chronic diseases. We employ data to identify the underlying causes, develop an evidence-based, personalized combination therapy, and work collaboratively with patients, caregivers, and health care providers to improve outcomes.
With a team of doctors, scientists, technology experts, and seasoned entrepreneurs, Muses Labs is bringing to market a next-generation personalized combination therapy for Alzheimer’s disease.
The approach we’re employing relies upon advanced software and big-data analytics, and incorporates decades of medical research. Muses Labs offers a service that utilizes the Internet and information technology innovations to make the Protocol practical and accessible to individuals with cognitive decline around the world.
The company was co-founded by CEO, Vik Chandra, and CTO, John Q. Walker, PhD. Chandra has more than 26 years of technology leadership and development experience, including two decades with IBM. Walker is a computer software veteran and serial entrepreneur with nearly four decades at IBM and three start-ups under his belt. He led the team in the development of the groundbreaking algorithms while managing data in a high security, HIPAA-compliant environment.
Chandra and Walker’s technology expertise is complimented by a Scientific Advisory Board, which consists of several of the top leading experts in memory loss, as well as additional experts in technology, medical affairs, research, and patient care who help shape the direction of the company’s technology and scientific protocols.
MUSES LABS LEADERSHIP TEAM
SCIENTIFIC ADVISORY BOARD
A Scientific Advisory Board, consisting of leading Alzheimer’s disease researchers and health care providers representing multiple institutions, shapes the direction of company’s technology and protocols.